Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis

Inclusion Criteria: * Aged 18 to 80 years * Active UC confirmed by endoscopy * Moderately to severely active UC defined as a 3-component Mayo Clinic score Exclusion Criteria: * Severe extensive colitis * Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis * Treatment with cyclosporine, tacrolimus, sirolimus, methotrexate, or mycophenolate mofetil within 16 weeks of screening * Treatment with a biologic agent (ie, anti TNFs, anti integrins, and anti interleukin 23) within 8 weeks prior to screening endoscopy * Any prior exposure to S1P receptor modulators, natalizumab, lymphocyte-depleting therapies (ie, alemtuzumab, anti CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)